Sierra Oncology Inc (SRRA) Stock
SRRA is no longer traded. Sierra Oncology was acquired by GSK on July 1, 2022.
Each SRRA share was exchanged for $55.00 in cash. Prices on this page are historical; the last trade was June 30, 2022 at $54.99.
See GSK stock →Sierra Oncology stock price history
SRRA final trading statistics
- Final close
- $54.99
- Final trading day
- Jun 30, 2022
- Market cap at delisting
- $1.34B
- Shares outstanding
- 24.42M
- Final 52-week range
- $14.91 – $55.19
- Avg. volume (final 3 mo.)
- 662,534
- All-time high (split-adj.)
- $50112.00 · Sep 2015
- All-time low (split-adj.)
- $8.88 · Apr 2020
- Return since IPO
- -99.9%
- Beta
- 0.02
- Book value / share
- $10.99
- Price / book
- 5.00
Sierra Oncology annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $0.00 | -$94.7M | -$7.15 |
| FY2020 | $300.0K | -$80.9M | -$7.74 |
| FY2019 | $0.00 | -$88.3M | -$29.48 |
| FY2018 | $0.00 | -$53.3M | -$30.00 |
| FY2017 | $0.00 | -$42.0M | -$8.65 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Sierra Oncology Inc
Sierra Oncology, Inc., a late-stage biopharmaceutical company, engages in researching, developing, and commercializing therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally bioavailable Janus kinase 1 (JAK 1), JAK2, and Activin A receptor type 1 (ACVR1) inhibitor. The company also develops SRA515, a selective bromodomain-containing protein 4 inhibitor; and SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1. It has the license agreements with Carna Biosciences, Inc. to develop and commercialize SRA141, a small molecule kinase inhibitor targeting Cdc7; AstraZeneca AB; and CRT Pioneer Fund LP. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is headquartered in San Mateo, California. As of July 1, 2022, Sierra Oncology, Inc. operates as a subsidiary of GSK plc.
Sierra Oncology stock FAQ
What happened to Sierra Oncology stock?
Sierra Oncology was acquired by GSK on July 1, 2022. Shareholders received $55.00 in cash for each share. SRRA stock stopped trading on the Nasdaq, with a final close of $54.99 on June 30, 2022.
What did Sierra Oncology shareholders receive?
Each SRRA share was converted into $55.00 in cash. The deal was valued at about $1.9 billion.
Is SRRA stock still trading?
No. SRRA was delisted from the Nasdaq on July 1, 2022 and no longer trades on a U.S. exchange.
What was the last price of SRRA stock?
SRRA closed at $54.99 on its final trading day, June 30, 2022, for a market value of about $1.34B.
What were Sierra Oncology's revenue and earnings in its last full fiscal year?
Sierra Oncology reported revenue of $0.00 and net income of -$94.7M in fiscal 2021, its last full year as a public company.
When did Sierra Oncology go public?
Sierra Oncology Inc stock began trading on July 16, 2015.